NDAINTRAMUSCULAR, SUBCUTANEOUSSOLUTIONPriority Review
Approved
Oct 2016
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
EVZIO (AUTOINJECTOR) (naloxone hydrochloride) by R-Pharm US is naloxone. First approved in 2016.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVZIO is an auto-injector formulation of naloxone hydrochloride, an opioid antagonist approved in 2016 for emergency treatment of opioid overdose. It rapidly reverses opioid-induced respiratory depression by competitively binding to mu-opioid receptors, displacing full agonists and producing acute withdrawal in opioid-dependent individuals. The auto-injector format enables rapid, lay-administered dosing in emergency settings.
Peak8.5 years to LOE
Product is at peak market penetration with established market presence; commercial teams likely focused on market maintenance and geographic expansion rather than growth initiatives.
Mechanism of Action
naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on EVZIO offers exposure to a public health-critical product in a peak lifecycle stage with established market presence and minimal competitive pressure, allowing focus on operational excellence and customer relationship management. Career development leans toward commercial and market access skills rather than clinical innovation, with opportunity to influence overdose reversal access and community health initiatives.
Brand Manager
Worked on EVZIO (AUTOINJECTOR) at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.